{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T18:13:44Z","timestamp":1792260824175,"version":"4.4.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82470189"],"award-info":[{"award-number":["No. 82470189"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82570237"],"award-info":[{"award-number":["No. 82570237"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-07067-0","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T01:04:42Z","timestamp":1779152682000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Zanubrutinib potentiates polatuzumab vedotin efficacy in DLBCL with concurrent CD79b upregulation"],"prefix":"10.1007","volume":"105","author":[{"given":"Xiaolong","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zipeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ailing","family":"Gui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichen","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qunling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"issue":"6","key":"7067_CR1","doi-asserted-by":"publisher","first-page":"e9046","DOI":"10.1002\/ccr3.9046","volume":"12","author":"HC Chang","year":"2024","unstructured":"Chang HC, Kang JC, Pu TW, Su RY, Chen CY, Hu JM (2024) Diffuse large B-cell lymphoma-induced intussusception: A case report and literature review. Clin Case Rep 12(6):e9046 Epub 20240618. https:\/\/doi.org\/10.1002\/ccr3.9046","journal-title":"Clin Case Rep"},{"issue":"5","key":"7067_CR2","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1007\/s00277-025-06412-z","volume":"104","author":"Y Ren","year":"2025","unstructured":"Ren Y, Tan H, Zhuang J, Cheng L, Yuan L, Ji L et al (2025) Polatuzumab Vedotin, zanubrutinib and rituximab (Pola-ZR) achieved rapid and deep response in untreated frail and elderly DLBCL. Ann Hematol 104(5):2823\u20132830 Epub 20250516. https:\/\/doi.org\/10.1007\/s00277-025-06412-z","journal-title":"Ann Hematol"},{"issue":"11","key":"7067_CR3","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","volume":"12","author":"M Pfreundschuh","year":"2011","unstructured":"Pfreundschuh M, Kuhnt E, Tr\u00fcmper L, Osterborg A, Trneny M, Shepherd L et al (2011) CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 12(11):1013\u20131022 PubMed PMID: 21940214","journal-title":"Lancet Oncol"},{"issue":"1","key":"7067_CR4","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1182\/asheducation-2016.1.366","volume":"2016","author":"B Coiffier","year":"2016","unstructured":"Coiffier B, Sarkozy C (2016) Diffuse large B-cell lymphoma: R-CHOP failure-what to do? Hematol Am Soc Hematol Educ Program 2016(1):366\u2013378. https:\/\/doi.org\/10.1182\/asheducation-2016.1.366. PubMed PMID: 27913503; PubMed Central PMCID: PMC6142522","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"19","key":"7067_CR5","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1182\/blood.2022018893","volume":"141","author":"SS Neelapu","year":"2023","unstructured":"Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO et al (2023) Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood 141(19):2307\u20132315. https:\/\/doi.org\/10.1182\/blood.2022018893. PubMed PMID: 36821768; PubMed Central PMCID: PMC10646788","journal-title":"Blood"},{"key":"7067_CR6","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1186\/s12935-020-01518-y","volume":"20","author":"C Xue","year":"2020","unstructured":"Xue C, Wang X, Zhang L, Qu Q, Zhang Q, Jiang Y (2020) Ibrutinib in B-cell lymphoma: single fighter might be enough? Cancer Cell Int 20:467 Epub 20200929. https:\/\/doi.org\/10.1186\/s12935-020-01518-y","journal-title":"Cancer Cell Int"},{"issue":"6","key":"7067_CR7","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1007\/s00277-021-04535-7","volume":"100","author":"Z Zhou","year":"2021","unstructured":"Zhou Z, Zhang L, Wang X, Li X, Li L, Fu X et al (2021) Ibrutinib combined with venetoclax for the treatment of relapsed\/refractory diffuse large B cell lymphoma. Ann Hematol 100(6):1509\u20131516 Epub 20210426. https:\/\/doi.org\/10.1007\/s00277-021-04535-7","journal-title":"Ann Hematol"},{"issue":"15","key":"7067_CR8","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1200\/jco.18.02403","volume":"37","author":"A Younes","year":"2019","unstructured":"Younes A, Sehn LH, Johnson P, Zinzani PL, Hong X, Zhu J et al (2019) Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. J Clin Oncol 37(15):1285\u20131295 Epub 20190322. https:\/\/doi.org\/10.1200\/jco.18.02403","journal-title":"J Clin Oncol"},{"key":"7067_CR9","doi-asserted-by":"publisher","unstructured":"Wilson WH, Wright GW, Huang DW, Hodkinson B, Balasubramanian S, Fan Y et al (2021) Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL. Cancer Cell 39(12):1643-53.e3. https:\/\/doi.org\/10.1016\/j.ccell.2021.10.006","DOI":"10.1016\/j.ccell.2021.10.006"},{"issue":"23","key":"7067_CR10","doi-asserted-by":"publisher","first-page":"6009","DOI":"10.1182\/bloodadvances.2020003010","volume":"4","author":"M Dimopoulos","year":"2020","unstructured":"Dimopoulos M, Sanz RG, Lee HP, Trneny M, Varettoni M, Opat S et al (2020) Zanubrutinib for the treatment of MYD88 wild-type Waldenstr\u00f6m macroglobulinemia: a substudy of the phase 3 ASPEN trial. Blood Adv 4(23):6009\u20136018. https:\/\/doi.org\/10.1182\/bloodadvances.2020003010. PubMed PMID: 33284944; PubMed Central PMCID: PMC7724905","journal-title":"Blood Adv"},{"issue":"26","key":"7067_CR11","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1182\/blood.2024024667","volume":"144","author":"JR Brown","year":"2024","unstructured":"Brown JR, Eichhorst B, Lamanna N, O\u2019Brien SM, Tam CS, Qiu L et al (2024) Sustained benefit of zanubrutinib vs ibrutinib in patients with R\/R CLL\/SLL: final comparative analysis of ALPINE. Blood 144(26):2706\u20132717. https:\/\/doi.org\/10.1182\/blood.2024024667. PubMed PMID: 39316666; PubMed Central PMCID: PMC11738031","journal-title":"Blood"},{"key":"7067_CR12","doi-asserted-by":"publisher","unstructured":"Camus V, Tilly H. Polatuzumab vedotin, an anti-CD79b antibody-drug conjugate for the treatment of relapsed\/refractory diffuse large B-cell lymphoma. Future Oncol. 2021;17(2):127-135. Epub 20200921. https:\/\/doi.org\/10.2217\/fon-2020-0675. PubMed PMID: 32954807.","DOI":"10.2217\/fon-2020-0675"},{"key":"7067_CR13","doi-asserted-by":"publisher","unstructured":"Malecek MK, Watkins MP, Bartlett NL. Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma. Expert Opin Biol Ther. 2021;21(7):831-839. Epub 20200615. https:\/\/doi.org\/10.1080\/14712598.2020.1777979.\u00a0PubMed PMID: 32500753.","DOI":"10.1080\/14712598.2020.1777979"},{"issue":"7Supplement","key":"7067_CR14","doi-asserted-by":"publisher","first-page":"4673","DOI":"10.1158\/1538-7445.Am2023-4673","volume":"83","author":"H Qi","year":"2023","unstructured":"Qi H, Wang F, Han B, Wang X, Qiang X, Zhang Z et al (2023) Abstract 4673: Therapeutic potential of polatuzumab vedotin for the treatment of diffuse large B-cell lymphoma. Cancer Res 83(7Supplement):4673. https:\/\/doi.org\/10.1158\/1538-7445.Am2023-4673","journal-title":"Cancer Res"},{"key":"7067_CR15","doi-asserted-by":"publisher","unstructured":"Zhang Y, Yuan L, Zhuang J, Wang Z, Zhang X, Wang W, et al. Zanubrutinib, Polatuzumab Vedotin and Rituximab (ZPR) Combination Regimen for Relapsed\/Refractory Patients with Diffuse Large B-Cell Lymphoma. Blood. 2023;142(Supplement 1):6304. https:\/\/doi.org\/10.1182\/blood-2023-185411","DOI":"10.1182\/blood-2023-185411"},{"key":"7067_CR16","unstructured":"Zhang YA-OX, Ren Y, Zhuang J, Yuan L, Wang Z, Zhang X et al. Effectiveness and safety of polatuzumab vedotin plus an anti-CD20 monoclonal antibody (Rituximab or Obinutuzumab) and zanubrutinib in relapsed\/refractory diffuse large B-Cell lymphoma. (2045-7634 (Electronic))"},{"issue":"6","key":"7067_CR17","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/s1470-2045(13)70122-0","volume":"14","author":"R Delarue","year":"2013","unstructured":"Delarue R, Tilly H, Mounier N, Petrella T, Salles G, Thieblemont C et al (2013) Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. Lancet Oncol 14(6):525\u2013533 Epub 20130409. https:\/\/doi.org\/10.1016\/s1470-2045(13)70122-0","journal-title":"Lancet Oncol"},{"issue":"9880","key":"7067_CR18","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/s0140-6736(13)60313-x","volume":"381","author":"D Cunningham","year":"2013","unstructured":"Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P et al (2013) Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet 381(9880):1817\u20131826 Epub 20130422. https:\/\/doi.org\/10.1016\/s0140-6736(13)60313-x","journal-title":"Lancet"},{"key":"7067_CR19","doi-asserted-by":"publisher","unstructured":"Wright GW, Huang DW, Phelan JD, Coulibaly ZA, Roulland S, Young RM et al (2020) A Probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell 37(4):551\u2009\u2013\u200968.e14. https:\/\/doi.org\/10.1016\/j.ccell.2020.03.015","DOI":"10.1016\/j.ccell.2020.03.015"},{"issue":"4","key":"7067_CR20","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trn\u011bn\u00fd M, Sharman JP et al (2022) Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N Engl J Med 386(4):351\u2013363 Epub 20211214. doi: 10.1056\/NEJMoa2115304. PubMed PMID: 34904799; PubMed Central PMCID: PMC11702892","journal-title":"N Engl J Med"},{"issue":"35","key":"7067_CR21","doi-asserted-by":"publisher","first-page":"3698","DOI":"10.1200\/jco-25-00925","volume":"43","author":"F Morschhauser","year":"2025","unstructured":"Morschhauser F, Salles G, Sehn LH, Herrera AF, Friedberg JW, Trn\u011bn\u00fd M et al (2025) Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma. J Clin Oncol 43(35):3698\u20133705 Epub 20250924. https:\/\/doi.org\/10.1200\/jco-25-00925","journal-title":"J Clin Oncol"},{"issue":"7","key":"7067_CR22","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1038\/leu.2015.48","volume":"29","author":"M Pfeifer","year":"2015","unstructured":"Pfeifer M, Zheng B, Erdmann T, Koeppen H, McCord R, Grau M et al (2015) Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes. Leukemia 29(7):1578\u20131586 Epub 20150224. https:\/\/doi.org\/10.1038\/leu.2015.48","journal-title":"Leukemia"},{"issue":"9","key":"7067_CR23","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1158\/2159-8290.Cd-24-0644","volume":"14","author":"E Leveille","year":"2024","unstructured":"Leveille E, Kothari S, Cosgun KN, Mlynarczyk C, M\u00fcschen M (2024) Tuning Responses to Polatuzumab Vedotin in B-cell Lymphoma. Cancer Discov 14(9):1577\u20131580. https:\/\/doi.org\/10.1158\/2159-8290.Cd-24-0644. PubMed PMID: 39228298","journal-title":"Cancer Discov"},{"issue":"2","key":"7067_CR24","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1200\/jco.19.00172","volume":"38","author":"LH Sehn","year":"2020","unstructured":"Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M et al (2020) Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol 38(2):155\u2013165 Epub 20191106. https:\/\/doi.org\/10.1200\/jco.19.00172","journal-title":"J Clin Oncol"},{"issue":"16","key":"7067_CR25","doi-asserted-by":"publisher","first-page":"e71162","DOI":"10.1002\/cam4.71162","volume":"14","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Ren Y, Zhuang J, Yuan L, Wang Z, Zhang X et al (2025) Effectiveness and Safety of Polatuzumab Vedotin Plus an Anti-CD20 Monoclonal Antibody (Rituximab or Obinutuzumab) and Zanubrutinib in Relapsed\/Refractory Diffuse Large B-Cell Lymphoma. Cancer Med 14(16):e71162 PubMed PMID: 40827409; PubMed Central PMCID: PMC12361929","journal-title":"Cancer Med"},{"key":"7067_CR26","doi-asserted-by":"publisher","unstructured":"Tkachenko A, Kupcova K, Havranek O. B-cell receptor signaling and beyond: the role of Ig\u03b1 (CD79a)\/Ig\u03b2 (CD79b) in normal and malignant B cells. Int J Mol Sci 25(1). https:\/\/doi.org\/10.3390\/ijms25010010","DOI":"10.3390\/ijms25010010"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07067-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07067-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07067-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T09:20:31Z","timestamp":1786785631000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07067-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":26,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["7067"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07067-0","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"28 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal experiments were approved by the Animal Ethics Committee of the Department of Laboratory Animal Science, Fudan University (Approval No. 202012005Z).","order":1,"name":"Ethics","label":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"331"}}